Mechanical, elution, and antibacterial properties of simplex bone cement loaded with vancomycin.

Prosthetic joint infection (PJI) is one of the most devastating failures in total joint replacement (TJR). Infections are becoming difficult to treat due to the emergence of multi-drug resistant bacteria. These bacteria produce biofilm on the implant surface, rendering many antibiotics ineffective by compromising drug diffusion and penetration into the infected area. With the introduction of new antibiotics there is a need to create benchmark data from the traditional antibiotic loaded bone cements. Vancomycin, one of the commonly used antibiotics, shows activity against Methicillin-resistant Staphylococcus aureus (MRSA) and S.epidermidis. In our study, vancomycin added to bone cement was evaluated for elution properties, antimicrobial properties, and mechanical properties of the bone cement. Vancomycin at five different loading masses (0.125, 0.25, 0.5, 1.0 and 2.0 g) was added to 40 g of Simplex™ P cement. Addition of vancomycin affected the mechanical properties and antimicrobial activity with significant differences from controls. Flexural and compression mechanical properties were compromised with added vancomycin. The flexural strength of samples with added vancomycin of 0.5 g and greater were not greater than ISO 5833 minimum requirements. 2.0 g of vancomycin added to bone cement was able to eliminate completely the four bacterial strains tested. 2.0 g of vancomycin also showed the highest mass elution from the cement over a 60-day period. Given the reduced flexural strength in samples with 0.5 g and greater of added vancomycin and the inability of vancomycin in amounts less than 2.0 g to eliminate bacteria, this study did not find an ideal amount of vancomycin added to Simplex™ P that meets both strength and antibacterial requirements.

Data for vancomycin elution, activity and impact on mechanical properties when incorporated into orthopedic bone cement.

In this article, we report data on the antibiotic elution and efficacy, and mechanical properties of Palacos bone cement with different amounts of added vancomycin (0.0, 0.125, 0.25, 0.5, 1.0, 2.0 g), see "Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement" (Bishop et al., 2018) [1]. Mechanical testing was performed for four-point bending, compression, and fracture toughness. The release characteristics of vancomycin was recorded for up to 60 days to estimate the elution profile. The eluted vancomycin efficacy at eliminating the four most common causative orthopedic implant pathogens is also reported.

Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement.

Infection incidence for total hip and knee arthroplasty (THA and TKA, respectively) is between 0.2% and 5% and results in approximately 100,000 device failures per year in the United States. Treatment requires prolonged systemic antibiotic therapy with additional surgical revisions. As a prophylactic measure against infection, antibiotics can be incorporated into bone cement during THA and TKA to provide drug administration at the implant site. Antibiotics in bone cement are only effective if they can elute out of the cement at a concentration that is active against common organisms. There is evidence that added antibiotics may affect the cement's mechanical properties, especially at higher dosages. The purposes of this investigation were to (i) determine the mechanical properties of a commercially available bone cement with the addition of vancomycin, (ii) determine the release characteristics of vancomycin added to bone cement, and (iii) evaluate eluted vancomycin efficacy at eliminating some of the most common causative orthopedic implant pathogens. Palacos bone cement was impregnated with incrementally larger clinically relevant weight percentages of vancomycin. Vancomycin is a treatment standard for invasive gram-positive infections, and Palacos cement is one of the most commonly used bone cements. After 21 days of curing in PBS, added masses of vancomycin greater than 0.5 g per 40.0 g cement packet decreased the cement's compressive yield strength to below ISO standard. The addition of vancomycin reduced the bone cement's mechanical properties in compression more than in bending. Vancomycin eluted from Palacos with a steady rise in eluted volume up to 8 days, after which non-therapeutic elution concentrations were observed up to a 60-day end point. The eluted concentration from samples with greater than 0.25 g vancomycin per Palacos packet was sufficient to eliminate a 103 colony forming unit per mL (CFU/mL) initial inoculum of S. aureus, including methicillin-resistant S. aureus (MRSA). However, none of the tested dosages were able to fully clear a 103 CFU/mL initial inoculum of a known high biofilm producing strain of S. epidermidis. When used for infection prophylaxis at the time of THA and TKA, the findings of this study do not support the addition of more than 0.5 g vancomycin to a 40 g packet of Palacos cement due to a reduction in compression yield strength below ISO standards. Vancomycin doses up to 0.5 g were shown to elute from the bone cement matrix and are effective at treating bacterial infections of 103 CFU/mL in bacterial strains of S. aureus, but may have limited effect against high-biofilm producing strains including S. epidermidis.